MyoPax: We repair muscle – the human muscle stem cell

PRINCIPAL INVESTIGATORS:
Prof. Dr. Simone Spuler,
Dr. Verena Schöwel
MDC & Charité

SUMMARY

Muscle wasting and weakness are leading symptoms of a wide variety of diseases. The entire muscle can be affected or only single muscles do not function, yet with dramatic impairment of life quality and life-threatening consequences. Muscle diseases are currently untreatable. In Europe alone, over 6 million citizens are affected. The team MyoPax develops an innovative autologous muscle stem cell therapy to treat muscle wasting. The team’s technological innovation enables highly standardized manufacturing of pure, native and highly regenerative muscle stem cells from small human muscle tissue specimens to treat acquired and inherited muscle diseases. The team has acquired follow-up funding and prepares to set up a startup company to clinically pursue the development of their approach to fight muscle diseases.

PROJECT ACHIEVEMENTS DURING SPARK

• Preclinical proof-of-concept, preclinical safety, PEI scientific advice meetings
• Planning of phase I/IIa clinical trial
• Science4Life award 2019 for “MyoPax” business concept, Charité Entrepreneur-ship summit award winner 2019
• BMBF Funding for clinical study in 2021

LONG-TERM GOALS

• Founding of a startup company in 2022
• Running the first in human clinical study in 2021

PREVIOUS SPARK FUNDING

• Track 1 2016